What is Kanyos?
Kanyos Bio is a biotechnology firm focused on pioneering antigen-specific immune tolerance technology. Originating from EPFL in Switzerland and operating as an independent affiliate of Anokion, Kanyos is dedicated to creating disease-modifying therapies for celiac disease and type-1 diabetes. The company leverages Anokion's immunotechnology expertise to address these specific autoimmune indications, aiming to provide novel treatment avenues for patients.
How much funding has Kanyos raised?
Kanyos has raised a total of $16M across 1 funding round:
Private Equity
$16M
Private Equity (2016): $16M with participation from Novo ventures, Versant Ventures, Novartis Venture Fund, and Astellas Pharma Inc
Key Investors in Kanyos
Novo ventures
Novo Ventures is a venture capital firm specializing in investments within the life sciences sector, particularly in biotechnology and pharmaceutical companies. They are known for supporting early-stage and growth-stage companies with the potential for significant scientific and commercial impact.
Versant Ventures
Versant Ventures is a prominent venture capital firm that partners with entrepreneurs to build and fund innovative biotechnology companies globally. With substantial capital under management, they have a strong history of successful IPOs and M&A transactions in the biotech industry.
Novartis Venture Fund
The Novartis Venture Fund is the corporate venture capital arm of Novartis, a global pharmaceutical giant. They invest in early-stage companies with innovative technologies and therapies that align with Novartis's strategic interests in healthcare and life sciences.
What's next for Kanyos?
With a major enterprise-level funding context and a recent strategic investment, Kanyos is poised for significant advancement in its therapeutic development pipeline. The company's focus on autoimmune diseases like celiac disease and type-1 diabetes, coupled with its strong technological foundation, suggests a strategic push towards clinical trials and further research. This backing will likely accelerate the progression of its antigen-specific immune tolerance technologies, potentially leading to groundbreaking treatments in the autoimmune space.
See full Kanyos company page
